Our projected milestones.

As ID4Pharma grows, we plan to grow and expand our research and development as well.  These are some of our projected milestones that we are currently on track

Some background information

2013 - ID4Pharma Launched

2014 - FIrst new drug patent was successfully licensed to Biotech company

2015 - Artificial Intelligent Chemogenomics knowledgebase Targethunter drug R&D platform

2016 - New Anti-Multiple Myeloma drug patent filed

Current Progress

2017 - Federal Fast-Track $2.3 Million awarded to ID4Pharma for FDA IND-enabling studies of anti-multiple myeloma P62ZZ to achieve new drug status

2017-2020 - PHASE I testing - to carry out scale-up chemistry and quality control assessments of the top p62zz compounds.  This aims to optimize and scale up chemistry synthesis routes for the identified compounds in order to prepare for IND-enabling preclinical studies
PHASE II - to measure in vitro potency and PK/PD oral Bioavailability of the p62zz compounds to find the efficacy  and toxicity of our drug.
This aims to perform preclinical evaluations of p62zz for test of efficacy and toxicity by using human MM xenographt mouse models in comparison of the current FDA approved anti-MM drugs (e.g. bortezomib)

Future Milestones

PHASE II  (cont.)- This aims to perform preclinical evaluations of p62zz for test of efficacy and toxicity by using human MM xenograft mouse models in comparison of the current FDA approved anti-MM drugs (e.g. bortezomib).

2022 - Prepare for FDA IND filing

2023 - FDA Phase I clinical trial - going for funding raised from investment companies and establishing strategic partnership with Pharm/biotech companies.